304873-65-2

Basic information

• Product Name: 2-Boc-amino-4-formylpyridine
• Synonyms: 2-Boc-amino-4-formylpyridine;N-(4-Formyl-2-pyridinyl)carbamic acid tert-butyl ester;tert-butyl 4-forMylpyridin-2-ylcarbaMate;2-Boc-amino-4-formylpyridin;(4-Formyl-pyridin-2-yl)-carbamic acid tert-butyl ester
• CAS NO: 304873-65-2
• Molecular Formula: C₁₁H₁₄N₂O₃
• Molecular Weight: 222.25
• Product Categories: pharmacetical
• Mol File: 304873-65-2.mol
• Article Data: 16

Chemical Properties

• Melting Point: 125-126℃
• Boiling Point: 308.8°Cat760mmHg
• Flash Point: 140.5°C
• Appearance: /
• Density: 1.212
• Vapor Pressure: 0.000666mmHg at 25°C
• Refractive Index: 1.579
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 12.20±0.70(Predicted)
• CAS DataBase Reference: 2-Boc-amino-4-formylpyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Boc-amino-4-formylpyridine(304873-65-2)
• EPA Substance Registry System: 2-Boc-amino-4-formylpyridine(304873-65-2)

Safety Data

• Hazardous Substances Data: 304873-65-2(Hazardous Substances Data)

Usage

General Description

2-Boc-amino-4-formylpyridine is a chemical compound that belongs to the pyridine family. It consists of a pyridine ring with a formyl group at the 4-position and a Boc-protected amino group at the 2-position. The Boc group is a protecting group commonly used in organic synthesis to prevent unwanted reactions at the amino group. 2-Boc-amino-4-formylpyridine has potential applications in organic synthesis as a building block for the preparation of various pharmaceuticals and organic compounds. It may also be used as a reagent in chemical reactions to introduce the formyl group into other molecules. Additionally, its Boc-protected amino group makes it a versatile intermediate in organic synthesis.

InChI:InChI=1/C11H14N2O3/c1-11(2,3)16-10(15)13-9-6-8(7-14)4-5-12-9/h4-7H,1-3H3,(H,12,13,15)

Upstream product

• 304873-62-9 (4-hydroxymethylpyridin-2-yl)carbamic acid tert-butyl ester 
• 6937-03-7 methyl 2-aminoisonicotinate 
• 639091-75-1 methyl 2-[(tert-butoxycarbonyl)amino]isonicotinate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 695-34-1 2-Amino-4-methylpyridine 
• 90101-20-5 tert-Butyl N-(4-methyl-pyridin-2-yl)carbamate 
• 13362-28-2 2-aminoisonicotinic acid 

Downstream Products

• 304873-62-9 (4-hydroxymethylpyridin-2-yl)carbamic acid tert-butyl ester 
• 943637-54-5 C₃₃H₃₄N₈O₃ 
• 1338814-70-2 N-(4-(4-(3-(3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)ureido)-1-naphthoyl)pyridin-2-yl)-2-(2-methoxyethoxy)acetamide 
• 1338815-64-7 1-(4-(2-aminoisonicotinoyl)naphthalen-1-yl)-3-(3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)urea 
• 1338814-71-3 1-(3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)-3-(4-((2-(3-ethylureido)pyridin-4-yl)methyl)naphthalen-1-yl)urea 
• 1338815-65-8 1-(4-((2-aminopyridin-4-yl)methyl)naphthalen-1-yl)-3-(3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)urea 
• 1446252-33-0 (E)-ethyl 3-(2-(tert-butoxycarbonylamino)pyridin-4-yl)-2-phenyl-acrylate 
• 1446252-36-3 (E)-ethyl 3-(2-aminopyridin-4-yl)-2-phenyl acrylate 
• 1446252-34-1 (E)-ethyl 3-(2-(tert-butoxycarbonylamino)pyridin-4-yl)-2-(4-fluorophenyl) acrylate 
• 1446252-27-2 tert-butyl [(Z)-4-(4-fluorostyryl)pyridin-2-yl] carbamate 
• 1446252-28-3 (Z)-4-(4-fluorostyryl)-pyridin-2-amine 
• 1446252-29-4 (Z)-tert-butyl 4-(4-fluorostyryl)pyridin-2-yl(isopropyl)carbamate 
• 1446252-30-7 (Z)-4-(4-fluorostyryl)-N-isopropylpyridin-2-amine 
• 1446252-37-4 (E)-ethyl 3-(2-aminopyridine-4-yl)-2-(4-fluorophenyl)acrylate 

Relevant articles and documents

AMINOPYRIDINE COMPOUNDS AND METHODS FOR THE PREPARATION AND USE THEREOF

The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its proteases arginine gingipain A/B (Rgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I and Formula III, as described herein, and pharmaceutically acceptable salts thereof.

COMPOSITION FOR THE TREATMENT OF IGF-1R EXPRESSING CANCER

The present invention relates to a method for the treatment of IGF-IR expressing cancers as well as to a compositions and a kit for said traitment. From one aspect, the invention reates to the combined use of a first antibody for the determination of the IGF-IR status of a cancer and a second antibody used as an ADC for the treatment of said cancer.

CONJUGATE OF MONOMETHYL AURISTATIN F AND TRASTUZUMAB AND ITS USE FOR THE TREATMENT OF CANCER

The present invention relates to an antibody-drug-conjugate. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody consisting of the Trastuzumab, said antibody being conjugated to at least one drug consisting of a monomethyl auristatin F derivative. The invention also comprises method of treatment and the use of said antibody-drug-conjugate for the treatment of cancer.